These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36506576)

  • 1. Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis.
    Xie L; Qi X; Wang X; He B; Wang Y; Zhang W; Yu Z; Deng M; Liang S; Lü M
    Front Pharmacol; 2022; 13():1042992. PubMed ID: 36506576
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Profile of Opicapone in the Management of Parkinson's Disease.
    Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
    J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A
    Rocha JF; Ebersbach G; Lees A; Tolosa E; Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Magalhães D; Gama H; Soares-da-Silva P
    Front Neurol; 2022; 13():994114. PubMed ID: 36081875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Istradefylline Versus Opicapone for "Off" Episodes in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Singh A; Gupta D; Dhaneria S; Sheth PG
    Ann Neurosci; 2021 Jan; 28(1-2):65-73. PubMed ID: 34733056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opicapone: A third generation COMT inhibitor.
    Greenwood J; Pham H; Rey J
    Clin Park Relat Disord; 2021; 4():100083. PubMed ID: 34316661
    [No Abstract]   [Full Text] [Related]  

  • 9. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
    JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
    Żegleń M; Śladowska K; Kawalec P; Brzostek T
    J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
    [No Abstract]   [Full Text] [Related]  

  • 15. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 16. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Fernández Pajarín G; Oropesa-Ruiz JM; Escamilla Sevilla F; Rahim López RRA; Muñoz Enríquez JG
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    Mov Disord; 2021 Feb; 36(2):415-423. PubMed ID: 33073879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.